FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W114597356> ?p ?o ?g. }

• W114597356 abstract "Abstract Background RRMM patients (pts) who have exhausted novel agent treatment (Tx) have limited effective options and short overall survival (OS). The presence of high-risk cytogenetics predicts shorter OS (Kumar, 2012). POM is a distinct oral IMiD® immunomodulatory agent with direct anti-myeloma, stromal cell-support inhibitory, and immune modulatory effects (Quach, 2010). The US FDA approved POM for the Tx of pts with ≥ 2 prior Tx, including lenalidomide (LEN) and bortezomib (BORT), and progressive disease (PD) on or within 60 days of completion of the last line of Tx. POM + LoDEX has demonstrated significant progression-free survival (PFS) and OS benefits with a tolerable safety profile in RRMM (San Miguel, EHA 2013). MM-003 compared POM + LoDEX vs HiDEX in RRMM pts who exhausted BORT and LEN. Methods Pts had to be refractory to last prior Tx (PD during Tx or within 60 days) and exhausted BORT and LEN after ≥ 2 consecutive cycles of each (alone or in combination). Pts were randomized 2:1 to receive 28-day cycles of POM 4 mg D1-21 + DEX 40 mg (20 mg for pts aged > 75 y) weekly or DEX 40 mg (20 mg for pts aged > 75 y) D1-4, 9-12, and 17-20. HiDEX was chosen as the comparator to isolate the effects of POM as at the time of trial design it was the standard salvage Tx for heavily pre-treated pts. Tx continued until PD or unacceptable toxicity. The primary endpoint was PFS. Secondary endpoints included OS, overall response rate (ORR; ≥ partial response), duration of Tx (DoT), and safety. These endpoints were further explored in relation to pt characteristics, cytogenetics, and prior antimyeloma Tx. Modified high-risk cytogenetics were defined as the presence of del(17) and/or t(4;14). Results 455 pts were randomized to POM + LoDEX (n = 302) or HiDEX (n = 153). Pt characteristics were well balanced. Pts were heavily pretreated: median 5 prior Tx (range, 2-17); 75% were refractory to BORT and LEN. Modified high-risk cytogenetics were detected in 25% of POM + LoDEX pts and 23% of HiDEX pts. With a median follow-up of 10 mos, POM + LoDEX significantly extended PFS and OS vs HiDEX (Figure). The OS benefit was observed despite 50% of HiDEX pts receiving subsequent POM. ORR was 31% vs 10% (P < .001). Advantages in ORR and median PFS were maintained for POM + LoDEX vs HiDEX regardless of modified high-risk cytogenetics (ORR: 23% vs 6%, P = .032; PFS: 3.8 vs 1.1 mos, HR = 0.46, P < .001) or standard-risk cytogenetics (ORR: 34% vs 7%, P < .001; PFS: 4.2 vs 2.3 mos, HR = 0.50, P < .001). Favorable median OS was observed regardless of cytogenetics (modified high risk: 9.9 vs 4.9 mos, HR = 0.69, P = .16; standard risk: 14.1 vs 10.0 mos, HR = 0.85, P = .42). Of note, 43% of HiDEX pts with high-risk and 56% of HiDEX pts with standard-risk cytogenetics received subsequent POM. Median DoT for all pts was 4.2 mos for POM + LoDEX pts and 3.9 mos for HiDEX pts receiving subsequent POM. To date, 27 (9%) POM + LoDEX pts have a DoT > 12 mos; 5 pts have received > 12 mos of POM after HiDEX. POM + LoDEX pts with DoT > 12 mos had lower baseline β2-microglobulin (β2-M) levels (52% vs 29% with β2-M < 3.5 mg/mL), higher serum albumin (85% vs 63% with ≥ 3.5 g/dL), and higher hemoglobin levels (70% vs 45% grade 0/1 hemoglobin) vs pts with POM DoT ≤ 12 mos. Importantly, for DoT > 12 mos vs ≤ 12 mos, there were no differences by LEN-refractory disease (95% vs 96%) or refractoriness to LEN as last prior Tx (30% vs 28%). Other similarly distributed factors included presence of modified high-risk cytogenetics, ISS stage, and ECOG performance status (PS; 0-1 vs 2). Similar trends were observed for pts with OS > 12 mos vs ≤ 12 mos and HiDEX pts receiving subsequent POM. The most frequent grade 3/4 adverse events (AEs) for POM + LoDEX vs HiDEX were neutropenia (48% vs 16%), anemia (33% vs 37%), and infections (30% vs 24%). Grade 3/4 DVT/PE was infrequent (1% vs 0%). Only 1% of pts in each arm experienced grade 3/4 peripheral neuropathy. Discontinuation due to AEs was low: 9% vs 10%. Conclusions This final analysis further confirms the significant PFS and OS benefits for POM + LoDEX vs HiDEX. High-risk cytogenetics did not impact median PFS for pts receiving POM + LoDEX. In this heavily pretreated population, 9% of POM + LoDEX pts had a DoT > 12 mos. Interestingly, no trends were observed in pts who received long-term Tx with regards to LEN as last prior Tx, high-risk cytogenetics, PS, or disease stage. POM + LoDEX should be considered a standard Tx option in RRMM pts with prior BORT and LEN. Disclosures: Dimopoulos: Celgene: Honoraria, Membership on an entity’s Board of Directors or advisory committees. Off Label Use: POM is approved in the US but not in Europe. Weisel:Celgene: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria. Song:Celgene: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau. Delforge:Celgene: Honoraria. Karlin:Celgene: Export board committee Other, Honoraria; Janssen: Honoraria. Goldschmidt:Celgene: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding. Moreau:Celgene: Honoraria, Speakers Bureau. Oriol:Celgene: Consultancy. Cavo:Onyx: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Millennium: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees. Alegre:Janssen: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity’s Board of Directors or advisory committees, Research Funding. Martinez-Lopez:Celgene: Honoraria, Research Funding. Chen:Celgene: Consultancy, Honoraria, Research Funding. Spencer:Celgene: Honoraria, Membership on an entity’s Board of Directors or advisory committees. Knop:Celgene: Honoraria. Bahlis:Celgene: Consultancy, Honoraria, Research Funding. Renner:Celgene: Consultancy, Honoraria, Travel support Other. Yu:Celgene: Employment, Equity Ownership. Hong:Celgene: Employment, Equity Ownership. Sternas:Celgene: Employment, Equity Ownership. Jacques:Celgene: Employment, Equity Ownership. Zaki:Celgene: Employment, Equity Ownership. San Miguel:Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Millenium: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Onyx: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees." @default.
• W114597356 created "2016-06-24" @default.
• W114597356 creator A5002073335 @default.
• W114597356 creator A5006799794 @default.
• W114597356 creator A5012405296 @default.
• W114597356 creator A5022522496 @default.
• W114597356 creator A5025168447 @default.
• W114597356 creator A5026611811 @default.
• W114597356 creator A5026970655 @default.
• W114597356 creator A5027311948 @default.
• W114597356 creator A5029390766 @default.
• W114597356 creator A5032373476 @default.
• W114597356 creator A5034182883 @default.
• W114597356 creator A5034430204 @default.
• W114597356 creator A5044377729 @default.
• W114597356 creator A5052238969 @default.
• W114597356 creator A5054952877 @default.
• W114597356 creator A5055916434 @default.
• W114597356 creator A5057834186 @default.
• W114597356 creator A5058588052 @default.
• W114597356 creator A5061069488 @default.
• W114597356 creator A5061821786 @default.
• W114597356 creator A5065238694 @default.
• W114597356 creator A5069106696 @default.
• W114597356 creator A5069449708 @default.
• W114597356 creator A5071926851 @default.
• W114597356 creator A5086115833 @default.
• W114597356 date "2013-11-15" @default.
• W114597356 modified "2023-10-18" @default.
• W114597356 title "Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)" @default.
• W114597356 doi "https://doi.org/10.1182/blood.v122.21.408.408" @default.
• W114597356 hasPublicationYear "2013" @default.
• W114597356 type Work @default.
• W114597356 sameAs 114597356 @default.
• W114597356 citedByCount "12" @default.
• W114597356 countsByYear W1145973562014 @default.
• W114597356 countsByYear W1145973562015 @default.
• W114597356 countsByYear W1145973562019 @default.
• W114597356 crossrefType "journal-article" @default.
• W114597356 hasAuthorship W114597356A5002073335 @default.
• W114597356 hasAuthorship W114597356A5006799794 @default.
• W114597356 hasAuthorship W114597356A5012405296 @default.
• W114597356 hasAuthorship W114597356A5022522496 @default.
• W114597356 hasAuthorship W114597356A5025168447 @default.
• W114597356 hasAuthorship W114597356A5026611811 @default.
• W114597356 hasAuthorship W114597356A5026970655 @default.
• W114597356 hasAuthorship W114597356A5027311948 @default.
• W114597356 hasAuthorship W114597356A5029390766 @default.
• W114597356 hasAuthorship W114597356A5032373476 @default.
• W114597356 hasAuthorship W114597356A5034182883 @default.
• W114597356 hasAuthorship W114597356A5034430204 @default.
• W114597356 hasAuthorship W114597356A5044377729 @default.
• W114597356 hasAuthorship W114597356A5052238969 @default.
• W114597356 hasAuthorship W114597356A5054952877 @default.
• W114597356 hasAuthorship W114597356A5055916434 @default.
• W114597356 hasAuthorship W114597356A5057834186 @default.
• W114597356 hasAuthorship W114597356A5058588052 @default.
• W114597356 hasAuthorship W114597356A5061069488 @default.
• W114597356 hasAuthorship W114597356A5061821786 @default.
• W114597356 hasAuthorship W114597356A5065238694 @default.
• W114597356 hasAuthorship W114597356A5069106696 @default.
• W114597356 hasAuthorship W114597356A5069449708 @default.
• W114597356 hasAuthorship W114597356A5071926851 @default.
• W114597356 hasAuthorship W114597356A5086115833 @default.
• W114597356 hasConcept C126322002 @default.
• W114597356 hasConcept C142424586 @default.
• W114597356 hasConcept C143998085 @default.
• W114597356 hasConcept C2776063141 @default.
• W114597356 hasConcept C2778524551 @default.
• W114597356 hasConcept C2780401358 @default.
• W114597356 hasConcept C2989005 @default.
• W114597356 hasConcept C71924100 @default.
• W114597356 hasConcept C86803240 @default.
• W114597356 hasConcept C87355193 @default.
• W114597356 hasConceptScore W114597356C126322002 @default.
• W114597356 hasConceptScore W114597356C142424586 @default.
• W114597356 hasConceptScore W114597356C143998085 @default.
• W114597356 hasConceptScore W114597356C2776063141 @default.
• W114597356 hasConceptScore W114597356C2778524551 @default.
• W114597356 hasConceptScore W114597356C2780401358 @default.
• W114597356 hasConceptScore W114597356C2989005 @default.
• W114597356 hasConceptScore W114597356C71924100 @default.
• W114597356 hasConceptScore W114597356C86803240 @default.
• W114597356 hasConceptScore W114597356C87355193 @default.
• W114597356 hasLocation W1145973561 @default.
• W114597356 hasOpenAccess W114597356 @default.
• W114597356 hasPrimaryLocation W1145973561 @default.
• W114597356 hasRelatedWork W1968654086 @default.
• W114597356 hasRelatedWork W1971305591 @default.
• W114597356 hasRelatedWork W1973888964 @default.
• W114597356 hasRelatedWork W1975916512 @default.
• W114597356 hasRelatedWork W1992470642 @default.
• W114597356 hasRelatedWork W2059876129 @default.
• W114597356 hasRelatedWork W2066713758 @default.
• W114597356 hasRelatedWork W2091773528 @default.
• W114597356 hasRelatedWork W2123159083 @default.
• W114597356 hasRelatedWork W2128903704 @default.
• W114597356 hasRelatedWork W2136541422 @default.
• W114597356 hasRelatedWork W2140579395 @default.
• W114597356 hasRelatedWork W2273325715 @default.

• next